2007/47/EC: why buying standards revisions can be frustrating
This article was originally published in Clinica
Manufacturers and consultants in the UK, and very likely elsewhere in the EU, who need to keep abreast with the latest standards changes may be questioning the costs of standards revised in the light of Directive 2007/47/EC which amends the medical device directives, given how minor some of the changes may be.
You may also be interested in...
Erik Hansson remains deputy head of devices in a move to the European Commission’s DG Sante from DG Grow. He now answers to a newly appointed devices head who shares a common educational background but whose recent pharmaceutical role may unsettle the devices industry.
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
It seems to be game over for anyone who might have been hoping the European Commission would do a U-turn on its decision to use the Italian CND nomenclature as the basis for communication in Eudamed, instead of the well-established GMDN. But GMDN is strong in its resolve to remain a vital global nomenclature service.